INTRODUCTION
ates leukocyte cell adhesion and antigen-specific T-cell activation by binding to /^-integrin molecules, such as The intercellular adhesion molecule-1 (ICAM-1, lymphocyte function-associated molecule-1 (LFA-1, CD54) is expressed on endothelial cells, astrocytes, CD1 la/18) and complement receptor type 3 (Mac-1, microglia, and B-and T-lymphocytes and is up-regulated CD 1 lb/18), expressed on leukocytes and macrophages in response to various stimuli (Frohman et al., 1989; (Smith et al., 1989; Diamond et al., 1990 ; Dustin and Satoh et al., 1991a; Sobel et al., 1990) . ICAM-1 medi-Springer, 1988; Rothlein et al., 1986 (Rothlein et al., 1991; Seth et al., 1991) .
Under normal conditions, cerebral endothelial cells show very low constitutive adhesion molecule expression, and only a few leukocytes and macrophages are found within the brain because of the impermeability of the blood-brain barrier (BBB) to resting white blood cells (Weckerle, 1993) . Transient (Abelda et al., 1994; Carlos and Harlan, 1994; Rössler et al., 1992; Zimmermann et al., 1992) . Leukocytes transmigrated into the brain release pro-inflammatory cytokines such as IL-1, IL-6, interferon (IFN)--y, and tumor necrosis factor (TNF)-a, which, in turn, up-regulate the expression of ICAM-1 on various cell types (Aloisi et al., 1992; Fabry et al., 1992; Frohman et al., 1989; Satoh et al., 1991b) and produce cytotoxic agents such as glutamate, oxygen radicals, and proteolytic enzymes (Zhuang et al., 1993) . The release of pro-inflammatory cytokines (Kossmann et al., 1996 (Kossmann et al., , 1997 Morganti-Kossmann et al., 1997) and neurotoxins (e.g., glutamate) within the brain is thought to aggravate BBB damage, leading to vasogenic and cytotoxic brain edema formation (Greenwood, 1991; Weckerle, 1993) , possibly resulting in a self-sustaining vicious circle (Cross et al., 1991; Staub et al., 1996) .
Various experimental models of ischemia revealed a correlation between the amount of accumulated granulocytes, increased cortical water content, and elevated intracranial pressure (Biagas et al., 1992; Schoettle et al., 1990; Zhuang et al., 1993) , reflecting the contribution of leukocytes to secondary brain damage. The administration of specific antibodies directed against ICAM-1 significantly reduced neutrophil accumulation, edema formation, infarction size, and neurologic damage after transient middle cerebral artery occlusion in rats (Bowes et al., 1993; Matsuo et al., 1994; Zhang et al., 1994) . In ICAM-1 knockout mice, infarct volume and neurologic deficits were markedly reduced after focal cerebral ischemia, and survival was significantly prolonged in comparison with ICAM-1 +/+ animals (Connolly et al., 1996) . An (Stocker et al., 1995 (Reiber and Felgenhauer, 1987 day 9, persisting to the end of the study period, whereas in group B there was only a transient elevation between days 9 and 13, followed by a rapid decrease to normal ranges (Fig. 1) .
In order to further determine whether higher sICAM-1 levels in CSF may depend on intrathecal release or on changes in serum, a CSF/serum ratio for sICAM-1 (Qsl-CAM-1) was assessed as previously shown for patients with neurologic diseases (Rieckmann et al., 1993 (Fig. 2) . This analysis showed a correlation between the levels of sICAM-1 in CSF and the Qa (r = 0.76, p < 0.001). However, some patients had sICAM-1 values in CSF above the normal range, although the BBB was only mildly to moderately disturbed (Fig. 2) (Rothlein et al., 1991; Seth et al., 1991; Budnik et al., 1996; Rieckmann et al., 1995a) or from a sustained cleavage of constitutively expressed membrane-bound ICAM-1. Apart from enzymatic cleavage, the soluble form of ICAM-1 is also believed to be produced anew, since two distinct mRNAs, one for membrane-bound ICAM-1 and one for soluble ICAM-1, have been demonstrated (Simmons et al., 1988; Staunton et al., 1989; Wakatsuki et al., 1995) . sICAM-1 in CSF may originate from cerebral endothelial cells and astrocytes, since these cell-types were shown to express (ICAM-1 in vitro (Frohman et al., 1989; Satoh et al., 1991a; Rieckmann et al., 1995a) and in vivo (Cannella et al., 1995; Sharief et al., 1993; Sobel et al., 1990; Shibayama et al., 1996; Isaksson et al., 1997) .
Since serum levels of sICAM-1 are up to 100-fold higher than those in CSF, a damaged BBB is required for passive translocation and penetration of these molecules into the central nervous system (CNS (Rieckmann et al., 1993) . It remains to be clarified whether sICAM-1 in CSF is elevated because of intrathecal production or because of increased leakage across the BBB.
Apart from traumatically induced damage of cerebral endothelial cells with subsequent passive translocation of serum sICAM-1, it is believed that trauma-related shearing of endothelial cells in itself induces enhanced expression of ICAM-1 (Nagel et al., 1994) . Supportive of this hypothesis is the finding that a few patients included in this study showed elevated sICAM-1 values with nearly normal BBB function (Fig. 2) , suggesting possible intrathecal release of sICAM-1. A slight dysfunction of the BBB may not be sufficient for a passive leakage of sICAM-1 from the periphery into CSF, since the molecular weight of sICAM-1 is greater than that of albumin (80-120 kD and 60 kD, respectively). Independently 405 from its origin, sICAM-1 present in the CNS may affect the function of the BBB, inducing the release of cytokines and neurotoxic factors by activated leukocytes (Sharief et al., 1993; Weckerle et al., 1993) . The exact origin of sICAM-1 in CSF, however, remains to be elucidated.
Although the Qa may only give a reference for the true BBB, it was used, since we hypothetize that the increased albumin concentration in CSF derives from the contused tissue and reaches the ventricular system as previously described (Duvdevani et al., 1995; Önal et al., 1997) (Baldwin et al., 1996; Kuroiwa et al., 1985) . Apart from glial and/or neuronal uptake (Tengvar and Ollson, 1982; Liu and Sturner, 1988; Hoshino et al., 1996) , a reverse vesicular transport from the extracellular space to blood via transendothelial passage may also occur (Vorbrodt et al., 1987) . Removal of extravasated proteins is thought to mainly result from pressure-driven bulk flow into the adjacent ventricular system (Rosenberg et al., 1980; Ohata et al., 1990 ) and the subarachnoid space (Ohata et al., 1992 (Stocker et al., 1995 (Rieckmann et al., 1995b) . Furthermore, sICAM-1 could possibly bind to circulating leukocytes within the next proximity or at a distance from the actual site of tissue damage and consequently antagonize the ICAM-1 interaction to its ligand LFA-1, expressed on leukocytes (Meyer et al., 1995) . Thus, sICAM-1 may possibly attenuate the extent of attraction, binding, and activation of leukocytes therefore preventing excessive migration of these cells and tissue damage (Gearing et al., 1992; Rothlein et al., 1991) .
Irrespective of its potential immunologie function, analysis of sICAM-1 in CSF may facilitate early diagnosis of inflammatory and immunologie response within traumatized brain parenchyma, since ICAM-1 is considered an early marker of immune activation and response (Diamond et al., 1990; Seth et al., 1991) .
To date, possible therapeutic interventions in patients with TBI are directed against resident membrane-bound ICAM-1 in order to minimize secondary brain damage. In animal models of ischémie brain injury, antibodies directed against ICAM-1 reduced neurologic deficits (Bowes et al., 1993; Matsuo et al., 1994; Zhang et al., 1994) . In humans, methylxanthine derivatives such as pentoxifylline have been shown to successfully modulate the immune system by attenuating the release of pro-inflammatory cytokines and reducing the expression of membrane-bound adhesion molecules (Mandi et al., 1995; Rieckmann et al., 1996) 
